NCT06235541撤回1 期
A Phase I Study to Evaluate the Safety and Tolerability of GENA-104A16 (Anti-contactin4 [CNTN4] Monoclonal Antibody [mAb]) in Patients With Advanced Solid Tumors
Genome & Company1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年2月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- To determine the MTD and RP2D
研究概览
简要总结
This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced solid tumors, for who no standard therapy exists, or standard therapy has failed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with histologically/cytologically confirmed unresectable, recurrent, or metastatic advanced solid tumors
- •Life expectancy of at least 3 months
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
- •Adequate organ function including hematological, hepatic, and renal functions.
- •Negative childbearing potential
- •Measurable disease as per RECIST v1.1 defined as at least 1 lesion
- •Patients who are willing and able to comply with scheduled cycles, treatment plans, laboratory tests, and other procedures
排除标准
- •A WOCBP who has a positive urine pregnancy test prior to treatment
- •Received prior systemic anti-cancer therapy within 4 weeks or 5 half-life periods (whichever is shorter) prior to the first dose of treatment
- •Received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
- •Received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention
- •Currently participating and receiving study treatments or has participated in a study of an investigational agent and received the study therapy or has used an investigational device within 4 weeks prior to the first dose of study treatment
- •Had an allogeneic tissue/solid organ transplant
- •A diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
- •A known additional malignancy that is progressing or has required active treatment within the past 3 years
- •A known active CNS metastases and/or carcinomatous meningitis
- •A known prior severe hypersensitivity reactions to monoclonal antibodies or any component in their formulation (Grade ≥3)
- •An active autoimmune disease that has required systemic treatment in past 2 years
- •A history of (non infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •An active infection requiring systemic therapy, or has received a course of antibiotics within 4 weeks prior to the first dose of treatment
- •A known history of human Immunodeficiency Virus (HIV) infection
- •A known history of Hepatitis B or known active Hepatitis C virus (HCV) infection
- •Diagnosed with Gliosis through a brain MRI and has experienced neurological conditions within 6 months before the first administration
- •Has any one or more clinically significant cardiovascular disease
- •A history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patients participation for the full duration of the study
研究组 & 干预措施
GENA104
Experimental
80 patients in total with histologically/cytologically confirmed unresectable, recurrent, or metastatic advanced solid tumors, for who no standard therapy exists, or standard therapy has failed will be enrolled in this study.
干预措施: GENA-104A16 (Drug)
结局指标
主要结局
To determine the MTD and RP2D
时间窗: 1 year
Incidence of dose limiting toxicity (DLT).
Incidence of Adverse Events
时间窗: 1 year
Assessed as per CTCAE v5.0
Incidence of Laboratory abnormalities
时间窗: 1 year
Assessed as per CTCAE v5.0
次要结局
- Half-life for Pharmacokinetic (PK) profile(1 year)
- Cmax for Pharmacokinetic (PK) profile(1 year)
- Tmax for Pharmacokinetic (PK) profile(1 year)
- AUC0-tlast for Pharmacokinetic (PK) profile(1 year)
- Clearance for Pharmacokinetic (PK) profile(1 year)
- Potential immunogenicity(1 year)
- Duration of response (DoR)(1 year)
- Progression free Survival (PFS)(1 year)
- Objective response rate (ORR)(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of AK138D1 in the Treatment of Advanced Solid TumorsSolid CancerNCT06730386Akeso100
Enrolling By Invitation
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsNCT06115642Shanghai Henlius Biotech367
招募中
1 期
A Study of HLX42 in Advanced/Metastatic Solid TumorsNCT06210815Shanghai Henlius Biotech102
招募中
1 期
A Study of FZ-AD005 in Patients With Advanced Solid TumorsAdvanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)NCT06424665Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.162
已完成
1 期
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06422520BeOne Medicines63